7.80
+0.14(+1.83%)
Currency In USD
| Previous Close | 7.66 |
| Open | 7.67 |
| Day High | 7.83 |
| Day Low | 7.65 |
| 52-Week High | 11.31 |
| 52-Week Low | 6 |
| Volume | 2.8M |
| Average Volume | 5.12M |
| Market Cap | 1.64B |
| PE | -156 |
| EPS | -0.05 |
| Moving Average 50 Days | 7.27 |
| Moving Average 200 Days | 8.25 |
| Change | 0.14 |
If you invested $1000 in BioCryst Pharmaceuticals, Inc. (BCRX) 10 years ago, it would be worth $795.92 as of January 01, 2026 at a share price of $7.8. Whereas If you bought $1000 worth of BioCryst Pharmaceuticals, Inc. (BCRX) shares 5 years ago, it would be worth $1,056.91 as of January 01, 2026 at a share price of $7.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
GlobeNewswire Inc.
Dec 12, 2025 12:00 PM GMT
–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
GlobeNewswire Inc.
Dec 03, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 197
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of trea